Business Wire

ees Europe: The Rise of Large-Scale Storage Systems – Driving Growth in the Storage Market and an Indispensable Pillar of the Energy Transition

Share

The energy transition has reached a crucial point. With increasing electricity generation from renewable sources, the need for effective grid stabilization solutions is growing. Large-scale battery storage systems play a key role. According to SolarPower Europe, the European market will grow by 30–40% annually, driven by the rise of large-scale storage. These systems will be central to discussions at ees Europe, the continent’s largest trade fair for batteries and energy storage, from 7 to 9 May 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327880309/en/

Falling installation and operating costs as well as lower prices for batteries are boosting the large-scale storage boom. © Eco Stor GmbH

Germany is experiencing rapid growth in large-scale battery storage. In early 2023, 1.4 GWh were installed, with projections of 61 GWh by 2027 and 136 GWh by 2045. A Fraunhofer study predicts 104 GWh by 2030 and 178 GWh by 2040. By the end of 2024/25, 650 battery storage inquiries totaling 226 GW had been received.

Price erosion and fast amortization

Two key factors drive the large-scale storage boom: declining installation and operating costs, mainly due to falling battery prices, and attractive revenue opportunities in balancing energy and electricity trading. Leonhard Probst from Fraunhofer ISE estimates a three-year amortization period. Given a 15-year battery lifespan, this allows 12 years of profit generation.

Industry association calls for regulatory reform

SolarPower Europe expects longer-duration storage systems (4 to 8 hours) to become standard in Europe. However, hurdles such as technical standards and storage restrictions must be addressed, according to Dries Acke, Vice President of SolarPower Europe.

Integration and flexibility

Large-scale storage systems efficiently integrate increasing renewable electricity into the grid, ensuring power availability when needed. These systems support both grid stability and overall system efficiency. For Germany, Frontier Economics estimates that by 2050, day-ahead trading alone could yield at least €12 billion in economic benefits, mainly from fuel savings and CO2 reduction.

Grid boosters ease the burden on the power grid

Grid boosters—specialized battery storage systems—help alleviate grid bottlenecks. Tennet is operating two projects where one facility absorbs excess wind power in the north while the other feeds power into the grid in the south. This approach offers a cost-effective alternative to building new power lines.

ees Forum and ees Europe Conference: Large-scale storage systems under the spotlight

At ees Forum (Hall C2, Stand C2.230) on the first day of the trade fair, visitors can attend a session on business models and applications for large-scale storage. The ees Europe Conference, running on 6 and 7 May 2025 at the International Congress Center Messe München, will focus on regulatory requirements, investor preferences, project development, market trends, and the business outlook for large-scale storage systems. Large-scale battery storage is becoming a key component of the energy transition, enabling renewable integration, grid stability, and economic benefits. With technological advancements, declining costs, and growing demand, energy storage is set to play an increasingly vital role in Europe's renewable energy landscape.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327880309/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye